HC Wainwright Analysts Lift Earnings Estimates for Prothena

Prothena Corporation plc (NASDAQ:PRTA) – Equities researchers at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Prothena in a research note issued to investors on Friday, February 20th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings of $1.81 per share for the year, up from their previous forecast of $1.80. HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share. HC Wainwright also issued estimates for Prothena’s Q4 2026 earnings at $1.14 EPS.

Prothena (NASDAQ:PRTA) last announced its earnings results on Thursday, February 19th. The biotechnology company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.67 million. Prothena had a negative return on equity of 62.53% and a negative net margin of 2,520.57%.

Several other brokerages also recently weighed in on PRTA. Wall Street Zen raised shares of Prothena from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Citizens Jmp set a $19.00 price objective on shares of Prothena in a research report on Monday, December 1st. UBS Group set a $36.00 target price on Prothena in a research report on Tuesday, October 28th. Deutsche Bank Aktiengesellschaft set a $19.00 target price on Prothena in a research note on Monday, December 1st. Finally, Chardan Capital raised Prothena to a “strong-buy” rating in a research note on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $22.00.

Prothena Stock Down 1.1%

Shares of PRTA opened at $8.97 on Monday. The business has a fifty day moving average of $9.22 and a 200 day moving average of $9.44. The company has a market cap of $482.86 million, a PE ratio of -1.98, a P/E/G ratio of 1.26 and a beta of -0.11. Prothena has a 52-week low of $4.32 and a 52-week high of $16.16.

Institutional Investors Weigh In On Prothena

Several hedge funds have recently modified their holdings of PRTA. Prospera Financial Services Inc purchased a new position in Prothena during the second quarter valued at approximately $61,000. Tower Research Capital LLC TRC lifted its stake in shares of Prothena by 571.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,709 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 10,815 shares during the last quarter. Corton Capital Inc. bought a new stake in Prothena during the second quarter valued at about $85,000. CWM LLC boosted its position in Prothena by 650.1% during the third quarter. CWM LLC now owns 10,246 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 8,880 shares in the last quarter. Finally, ProShare Advisors LLC purchased a new position in Prothena in the fourth quarter valued at about $100,000. Hedge funds and other institutional investors own 97.08% of the company’s stock.

Prothena Company Profile

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.